Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial Nature.com Nawigacja wpisu NanoVation Therapeutics Announces Multi-Target Partnership with Novo Nordisk to Develop Genetic Medicines Targeting Cardiometabolic and Rare Diseases – Business Wire Medical College of Wisconsin executive VP and dean of medical school to step down by the end of the year – Milwaukee Journal Sentinel
